CapWealth Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

CapWealth Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8	Closed	-$109K	–	102
2017 Q4	$109K	Hold	8	–	–	0.02%	98
2017 Q3	$108K	Hold	8	–	–	0.02%	96
2017 Q2	$74K	Hold	8	–	–	0.01%	97
2017 Q1	$58K	Hold	8	–	–	0.01%	96
2016 Q4	$42K	Hold	8	–	–	0.01%	91
2016 Q3	$53K	Hold	8	–	–	0.01%	139
2016 Q2	$54K	Hold	8	–	–	0.01%	138
2016 Q1	$59K	Hold	8	–	–	0.02%	129
2015 Q4	$91K	Hold	8	–	–	0.02%	100
2015 Q3	$89K	Hold	8	–	–	0.02%	96
2015 Q2	$121K	Hold	8	–	–	0.03%	97
2015 Q1	$113K	Buy	8 +1	+14%	+$12K	0.03%	102
2014 Q4	$58K	Buy	7 +6	+600%	+$52.1K	0.01%	84
2014 Q3	$17K	Buy	+1	New	+$10.9K	﹤0.01%	199

Other funds holding GLMD

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CapWealth Advisors's GLMD Position: Q1 2018 in Review

CapWealth Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q1 2018, closing a stake of 8 shares — an estimated $109K sold.

CapWealth Advisors first reported a position in GLMD in Q3 2014 and held it in 14 quarters. The position peaked at $121K in Q2 2015. 18 funds tracked by Wall St. Rank hold GLMD as of Q1 2018.

CapWealth Advisors reported no remaining Galmed Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
CapWealth Advisors sold 8 Galmed Pharmaceuticals shares in Q1 2018, an estimated $109K.
CapWealth Advisors first reported a position in Galmed Pharmaceuticals in Q3 2014 and held it in 14 quarters.
CapWealth Advisors's Galmed Pharmaceuticals position peaked at $121K in Q2 2015.
18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2018.

Based on CapWealth Advisors's 13F filing for Q1 2018, filed 11 May 2018.